The classic website will no longer be available as of June 25, 2024. Please use the modernized ClinicalTrials.gov.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

First-in-Human Study of OKI-219 in Advanced Solid Tumors and Advanced Breast Cancer (PIKture-01)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT06239467
Recruitment Status : Recruiting
First Posted : February 2, 2024
Last Update Posted : March 8, 2024
Sponsor:
Information provided by (Responsible Party):
OnKure, Inc.

Brief Summary:
OKI-219-101 is a Phase 1a/1b, open-label, multicenter, dose-escalation study designed to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PDx), and efficacy of OKI-219 as monotherapy and in combination with fulvestrant or trastuzumab. Phase 1a (Part A) will investigate escalating doses of OKI-219 monotherapy, and Phase 1b will investigate OKI-219 (at a tolerated dose determined in Part A) in combination with standard dose fulvestrant (Part B) or standard dose trastuzumab (Part C). Participants will continue to receive study treatment until disease progression, intolerable toxicity, or other study treatment withdrawal criteria are met.

Condition or disease Intervention/treatment Phase
Advanced Cancer Breast Cancer Drug: OKI-219 Drug: Fulvestrant Drug: Trastuzumab Phase 1

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 150 participants
Allocation: Randomized
Intervention Model: Sequential Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: PIKture-01: First-in-Human Study of the PI3KαH1047R Mutant-Selective Inhibitor OKI-219 as Monotherapy in Participants With Advanced Solid Tumors and in Combination With Endocrine Therapy or HER2-Targeted Therapy in Participants With Advanced Breast Cancer
Actual Study Start Date : March 1, 2024
Estimated Primary Completion Date : June 1, 2026
Estimated Study Completion Date : August 1, 2027

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Breast Cancer
Drug Information available for: Fulvestrant

Arm Intervention/treatment
Experimental: Phase 1a: Part A Dose Escalation
OKI-219 Monotherapy Dose Escalation in participants with advanced solid tumors with the PI3Kα1047R mutation
Drug: OKI-219
Oral twice daily

Experimental: Phase 1b: Part B Dose Escalation
OKI-219 + Fulvestrant Dose Escalation in participants with HR+/HER2- locally advanced, unresectable or metastatic breast cancer with the PI3KαH1047R mutation
Drug: OKI-219
Oral twice daily

Drug: Fulvestrant
Intramuscular injection

Experimental: Phase 1b: Part B Dose Optimization
OKI-219 + Fulvestrant Dose Optimization in participants with HR+/HER2- locally advanced, unresectable or metastatic breast cancer with the PI3KαH1047R mutation
Drug: OKI-219
Oral twice daily

Drug: Fulvestrant
Intramuscular injection

Experimental: Phase 1b: Part C Dose Escalation
OKI-219 + Trastuzumab Dose Escalation in participants with HR±/HER2+ locally advanced, unresectable or metastatic breast cancer with the PI3KαH1047R mutation
Drug: OKI-219
Oral twice daily

Drug: Trastuzumab
Intravenous (IV)

Experimental: Phase 1b: Part C Dose Optimization
OKI-219 + Trastuzumab Dose Optimization in participants with HR±/HER2+ locally advanced, unresectable or metastatic breast cancer with the PI3KαH1047R mutation
Drug: OKI-219
Oral twice daily

Drug: Trastuzumab
Intravenous (IV)




Primary Outcome Measures :
  1. Identify maximum tolerated dose (MTD) in monotherapy or in combination with fulvestrant or trastuzumab [ Time Frame: Cycle 1 (First 28 or 21 days on treatment) ]
    Frequency of participants experiencing dose-limiting toxicities during the first 28-day cycle

  2. Assess safety of OKI-219 as monotherapy or in combination with fulvestrant or trastuzumab: incidence of SAEs [ Time Frame: Through 30 days after last dose, an average of 1 year ]
    Number and type of SAEs experienced by participants during treatment and follow-up

  3. Assess safety of OKI-219 as monotherapy or in combination with fulvestrant or trastuzumab: incidence of Grade 2 or greater treatment emergent adverse events [ Time Frame: Through 30 days after last dose, an average of 1 year ]
    Number of treatment-emergent adverse events (TEAEs) equal or greater than Grade 2 experienced during treatment and follow-up

  4. Assess rate of dose modifications during treatment with OKI-219 as monotherapy or in combination with fulvestrant or trastuzumab [ Time Frame: Through last study dose, an average of 1 year ]
    rate of dose modifications


Secondary Outcome Measures :
  1. Assess the plasma PK of OKI-219 following single and multiple doses as monotherapy or in combination with fulvestrant or trastuzumab: maximum plasma concentration (Cmax) [ Time Frame: Through cycle 6 of treatment (up to 28 weeks) ]
    PK of OKI-219: Cmax

  2. Assess the plasma PK of OKI-219 following single and multiple doses as monotherapy or in combination with fulvestrant or trastuzumab: time of maximum plasma concentration (Tmax) [ Time Frame: Through cycle 6 of treatment (up to 28 weeks) ]
    PK of OKI-219: Tmax

  3. Assess the plasma PK of OKI-219 following single and multiple doses as monotherapy or in combination with fulvestrant or trastuzumab: area under the plasma concentration-time curve (AUC) [ Time Frame: Through cycle 6 of treatment (up to 28 weeks) ]
    PK of OKI-219: AUC

  4. Assess the plasma PK of OKI-219 following single and multiple doses as monotherapy or in combination with fulvestrant or trastuzumab: terminal elimination half-life time (t1/2) [ Time Frame: Through cycle 6 of treatment (up to 28 weeks) ]
    PK of OKI-219: t1/2

  5. To estimate the preliminary antitumor activity of OKI-219 as monotherapy and in combination with fulvestrant or trastuzumab: objective response rate (ORR) [ Time Frame: Up to approximately 36 months ]
    ORR per investigator assessed Response Evaluation Criteria in Solid Tumors, version 1.1 (RECIST 1.1)

  6. To estimate the preliminary antitumor activity of OKI-219 as monotherapy and in combination with fulvestrant or trastuzumab: clinical benefit rate (CBR) [ Time Frame: Up to approximately 36 months ]
    CBR per investigator assessed Response Evaluation Criteria in Solid Tumors, version 1.1 (RECIST 1.1)

  7. Dose optimization only: to estimate the preliminary antitumor activity of OKI-219 as monotherapy and in combination with fulvestrant or trastuzumab: progression free survival (PFS) [ Time Frame: Up to approximately 36 months ]
    PFS per investigator assessed Response Evaluation Criteria in Solid Tumors, version 1.1 (RECIST 1.1)

  8. To assess the dose-response impact of OKI-219 as monotherapy and in combination with fulvestrant or trastuzumab on PI3KαH1047R ctDNA levels [ Time Frame: Through last study dose, an average of 1 year ]
    Changes in PI3KαH1047R ctDNA on treatment and end of treatment (EOT) compared to baseline.

  9. To determine the impact of OKI-219 dosing as monotherapy and in combination with fulvestrant or trastuzumab on blood glucose and insulin [ Time Frame: Through last study dose, an average of 1 year ]
    Changes in plasma glucose, serum insulin, serum c-peptide levels, and hemoglobin A1c (HbA1c) will be evaluated on treatment compared to baseline.

  10. To assess the PDx activity of OKI-219 as monotherapy and in combination with fulvestrant or trastuzumab [ Time Frame: Through last study dose, an average of 1 year ]
    PDx activity will be evaluated with serial tumor biopsy samples assessed for PI3K/AKT/mTOR downstream pathway changes.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Participants with advanced solid tumors with documented evidence of a PI3KαH1047R mutation in tumor tissue and/or blood (ie, ctDNA) obtained during the course of normal clinical care in a Clinical Laboratory Improvement Amendments (CLIA)- or similarly certified laboratory.
  2. Cohort-specific disease requirements:

    1. Phase 1a Monotherapy Dose Escalation (Part A):

      • Participants with advanced solid tumors and no effective standard therapy option or for whom standard-of-care therapy is not available or not appropriate.
      • Participants with HR+/HER2- locally advanced, unresectable or metastatic breast cancer, must have received at least 1 prior line of hormonal therapy and at least 1 prior line of cyclin-dependent kinase (CDK)4/6-inhibitor in the advanced or metastatic setting unless contraindicated.
      • Participants with HER2+ locally advanced, unresectable or metastatic breast cancer must have received prior taxane, trastuzumab, pertuzumab, tucatinib, and trastuzumab deruxtecan unless unavailable in the region or contraindicated.
      • Participants with HER2-low breast cancer must have received prior trastuzumab deruxtecan unless unavailable in the region or contraindicated.
      • Participants with colorectal cancer must have Kirsten rat sarcoma viral oncogene homolog (KRAS) wild-type disease.
    2. Phase 1a Monotherapy Backfill Additional Criterion (Part A):

      - Participants must have a tumor amenable to predose, post dose and end-of- treatment tumor biopsy

    3. Phase 1b Dose Escalation and Dose Optimization: OKI-219 + fulvestrant (Part B):

      • Participants with locally advanced, unresectable or metastatic HR+/HER2- breast cancer must have received at least 1 prior line of hormonal therapy in the advanced or metastatic setting and at least 1 prior CDK4/6-inhibitor unless contraindicated or unavailable in the region.
      • Participants must be post-menopausal or agree to ovarian suppression with a gonadotropin-releasing hormone (GnRH) agonist started at least 4 weeks prior to the first dose of study drug.
      • Participants with HER2-low breast cancer must have received prior trastuzumab deruxtecan unless unavailable in the region or contraindicated.
      • Candidate for fulvestrant therapy.
    4. Phase 1b Dose Escalation and Dose Optimization: OKI-219 + trastuzumab (Part C):

      • Participants with HR±/HER2+ locally advanced, unresectable or metastatic breast cancer must have received prior taxane, trastuzumab, pertuzumab, tucatinib, and trastuzumab deruxtecan unless unavailable in the region or contraindicated.
      • Candidate for trastuzumab therapy.
      • Left ventricular ejection fraction (LVEF) > 50%
  3. ECOG PS 0 to 1.
  4. Life expectancy > 12 weeks.
  5. Have adequate archival tumor tissue (block or 10 slides) from a core or surgical biopsy, excluding bone biopsies. If no archival tissue is available, a fresh biopsy must be performed.
  6. Adequate organ and marrow function, defined as follows:

    1. Absolute neutrophil count ≥ 1.5 × 10^9/L;
    2. Platelets ≥ 100,000/μL;
    3. Hemoglobin ≥ 8.0 g/dL;
    4. Total bilirubin within the institutional upper limit of normal (ULN);
    5. Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 2.5 × ULN;
    6. Creatinine clearance calculated using the Cockcroft-Gault formula ≥ 60 mL/min.
  7. All prior clinically significant treatment-related toxicities must have resolved to Grade ≤ 1 or baseline (per CTCAE version 5.0) except for alopecia. Participants with stable Grade 2 peripheral neuropathy or endocrinopathies with stable endocrine replacement therapy are eligible. Participants with irreversible toxicity that is not reasonably expected to be exacerbated by study treatment (eg, vitiligo or hearing loss) may be eligible after discussion with the Sponsor.
  8. Able to swallow and tolerate oral medications.
  9. At least 1 measurable lesion based on RECIST version 1.1.

Exclusion Criteria:

  1. Treatment with any investigational product or other anticancer therapy (including chemotherapy, antibody-drug conjugates, targeted agents, and immunotherapy) within 14 days or 5 half-lives, whichever is shorter, of the first dose of study drug.
  2. Prior treatment with the PI3KαH1047R mutant-selective inhibitor LOXO-783.
  3. Participants with a known KRAS mutation.
  4. Participants with a known deleterious mutation in PTEN or negative for PTEN protein expression by IHC.
  5. Major surgery or wide-field radiation within 28 days or limited field palliative radiation within 7 days prior to the first dose of study drug.
  6. Known active central nervous system metastasis.
  7. Treatment with systemic corticosteroids at a dose of > 10 mg of prednisone or equivalent at the time of enrollment.
  8. Uncontrolled Type 1 or Type 2 diabetes.
  9. Known history of Crigler-Najjar syndrome.
  10. Known Gilbert's syndrome.
  11. Participants who are pregnant or nursing.
  12. Concomitant active malignancy or previous malignancy within 2 years of the time of enrollment.
  13. Impaired cardiovascular function or clinically significant cardiovascular disease, including any of the following:

    1. History of acute myocardial infarction or acute coronary syndromes in the 6 months prior to enrollment.
    2. Symptomatic congestive heart failure (Grade 2 or higher), history or current evidence of clinically significant cardiac arrhythmia and/or conduction abnormality in the last 6 months except for medically managed atrial fibrillation or paroxysmal supraventricular tachycardia.
    3. Uncontrolled hypertension despite medical management
  14. Any medical condition that would impair the administration or absorption of oral agents.
  15. History of symptomatic drug-induced pneumonitis.
  16. Participants with HIV infection and any of the following:

    1. Cluster of differentiation 4 (CD4) count < 350 cells/μL;
    2. A history of AIDS with an opportunistic infection within 12 months prior to enrollment;
    3. Not on established antiretroviral therapy for at least 4 weeks prior to enrollment and HIV viral load > 400 copies/mL.
  17. Positive hepatitis B virus (HBV) core antibody unless antigen negative and HBV DNA polymerase chain reaction (PCR) is negative. In the case of participants with positive HBV core antibody with antigen negative and negative HBV DNA PCR, the Investigator should consider the use of prophylaxis for reactivation.
  18. Positive hepatitis C virus (HCV) antibody unless PCR negative for HCV RNA with completion of curative antiviral treatment.
  19. History or current evidence of congenital long QT syndrome.
  20. QTc interval corrected using Fridericia's formula (QTcF) > 470 msec on screening ECG.
  21. Use of any of the following within 1 week prior to the first dose of study drug or ongoing need for these medications throughout the treatment phase:

    1. Proton pump inhibitors (PPIs);
    2. Medications that are moderate or strong inhibitors or inducers of uridine diphosphate-glucuronosyltransferase (UGT)2B7;
    3. Sensitive substrates of organic anion transporter (OAT)1, OAT3, breast cancer resistance protein (BCRP), or OATP1B1 with known risk for clinically relevant drug interactions related to transporter inhibition (note: the 1-week washout period prior to the first dose is not necessary for these substrates).

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT06239467


Contacts
Layout table for location contacts
Contact: OnKure, Inc. 720-307-2892 info@onkure.com

Locations
Layout table for location information
United States, Virginia
NEXT Oncology Virginia Recruiting
Fairfax, Virginia, United States, 22031
Contact: Blake Patterson       mailto:bpatterson@nextoncology.com   
Sponsors and Collaborators
OnKure, Inc.
Layout table for additonal information
Responsible Party: OnKure, Inc.
ClinicalTrials.gov Identifier: NCT06239467    
Other Study ID Numbers: OKI-219-101
First Posted: February 2, 2024    Key Record Dates
Last Update Posted: March 8, 2024
Last Verified: March 2024
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by OnKure, Inc.:
PI3K
Solid Tumor
Breast Cancer
OKI-219
trastuzumab
fulvestrant
Additional relevant MeSH terms:
Layout table for MeSH terms
Breast Neoplasms
Neoplasms by Site
Neoplasms
Breast Diseases
Skin Diseases
Trastuzumab
Fulvestrant
Antineoplastic Agents, Immunological
Antineoplastic Agents
Antineoplastic Agents, Hormonal
Estrogen Receptor Antagonists
Estrogen Antagonists
Hormone Antagonists
Hormones, Hormone Substitutes, and Hormone Antagonists
Physiological Effects of Drugs